Science Explorer Interactive view Map
Company · La Chaux-de-Fonds · Switzerland

Glenmark Pharmaceuticals (Switzerland)

glenmarkpharma.comROR OpenAlex
Research works
18
▼ 25% vs 2013–17
Citations
310
17.2 per fractional work
Top-10% rate
16.0%
record average 16.5%
Open access
59%
world 28%

Not ranked overall: Glenmark Pharmaceuticals (Switzerland) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 9.99× its world share, 0 worksBiochemistry, Geneti…Immunology and Microbiology: 2.38× its world share, 0 worksImmunology and Micro…Engineering: 0.74× its world share, 0 worksEngineeringEnvironmental Science: 2.25× its world share, 0 worksEnvironmental ScienceMaterials Science: 3.20× its world share, 0 worksMaterials ScienceMedicine: 0.57× its world share, 0 worksMedicine1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 10.0×. Every wedge is a field page.

Which research topics does Glenmark Pharmaceuticals (Switzerland) publish most on?

By volume in 2022–2025: RNA and protein synthesis mechanisms, Viral Infectious Diseases and Gene Expression in Insects, RNA Research and Splicing and Monoclonal and Polyclonal Antibodies Research.

RNA and protein synthesis mechanisms: 0 fractional worksViral Infectious Diseases and Gene Expression in Insects: 0 fractional worksRNA Research and Splicing: 0 fractional worksMonoclonal and Polyclonal Antibodies Research: 0 fractional worksNanotechnology research and applications: 0 fractional worksNanoparticles: synthesis and applications: 0 fractional worksMicroplastics and Plastic Pollution: 0 fractional works
Molecular BiologyRadiology, Nuclear Medicine and ImagingBiomedical EngineeringMaterials Chemistry1 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 RNA and protein synthesis mechanisms Molecular Biology 0 works
  2. 2 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 0 works
  3. 3 RNA Research and Splicing Molecular Biology 0 works
  4. 4 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
  5. 5 Nanotechnology research and applications Biomedical Engineering 0 works
  6. 6 Nanoparticles: synthesis and applications Materials Chemistry 0 works
  7. 7 Microplastics and Plastic Pollution Pollution 0 works
  8. 8 Immune Cell Function and Interaction Immunology 0 works
  9. 9 Multiple Myeloma Research and Treatments Hematology 0 works
  10. 10 Glycosylation and Glycoproteins Research Molecular Biology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available58.9%not open41.1%

World: 28% of research is openly available.

with international co-authors58.9%domestic only41.1%

World: 19% is written across borders.

How has Glenmark Pharmaceuticals (Switzerland)'s research output changed?

Output in 2018–2022 was 25% lower than in 2013–2017.

1990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in La Chaux-de-Fonds

All research institutions in La Chaux-de-Fonds

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.